Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 3/20 | 0.40 |
| ▸ | TTK | P33981 | 2/20 | 0.33 |
| ▸ | LATS1 | O95835 | 1/20 | 0.32 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20164742 | 0.99 | SLC29A1 (0.40) | SLC29A1TTKLATS1LATS2MEN1 | |
| SCHEMBL16094312 | 0.81 | SLC29A1 (0.51) | SLC29A1MEN1LMNAKMT2A | |
| Hydrochloric Acid SCHEMBL17494536 | 0.79 | SLC29A1 (0.50) | SLC29A1MEN1LMNAKMT2A | |
| SCHEMBL20164443 | 0.76 | SLC29A1 (0.66) | SLC29A1MEN1KMT2A | |
| SCHEMBL20164342 | 0.75 | SLC29A1 (0.47) | SLC29A1 | |
| Hydrochloric Acid SCHEMBL20164696 | 0.75 | SLC29A1 (0.64) | SLC29A1MEN1KMT2A | |
| SCHEMBL20164523 | 0.74 | SLC29A1 (0.62) | SLC29A1KMT2A | |
| SCHEMBL16094829 | 0.74 | SLC29A1 (0.71) | SLC29A1MEN1KMT2A | |
| SCHEMBL20164741 | 0.73 | SLC29A1 (0.41) | SLC29A1MEN1LMNAKMT2A | |
| Hydrochloric Acid SCHEMBL20164421 | 0.73 | SLC29A1 (0.60) | SLC29A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180141953-A1 | Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same | NEURAD LTD. (IL) | 2018-05-24 | — | — | US | claimed |
| US-20250057848-A1 | GAL475 COMPOSITIONS AND METHODS OF USE THEREOF | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2025-02-20 | — | — | US | disclosed |
| EP-3316890-B1 | NOVEL BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF MAKING AND USING SAME | NEURAD LTD (IL) | 2023-09-06 | — | — | EP | disclosed |
| EP-3316890-B1 | NOVEL BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF MAKING AND USING SAME | NEURAD LTD (IL) | 2023-09-06 | — | — | EP | disclosed |
| US-10294228-B2 | Breathing control modulating compounds, and methods of making and using same | NEURAD LTD. (IL) | 2019-05-21 | — | — | US | disclosed |
| US-10294228-B2 | Breathing control modulating compounds, and methods of making and using same | NEURAD LTD. (IL) | 2019-05-21 | — | — | US | disclosed |
| US-20180141953-A1 | Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same | NEURAD LTD. (IL) | 2018-05-24 | — | — | US | disclosed |
| US-20180141953-A1 | Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same | NEURAD LTD. (IL) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141953-A1 | Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same | MTNR1B, CHRM3, PER2 | SLC29A1 4472/4885TTK 3899/4885LATS1 3741/4885 |
| US-20250057848-A1 | GAL475 COMPOSITIONS AND METHODS OF USE THEREOF | GPR119, GPR35, GPR55 | SLC29A1 2077/4885TTK 3905/4885LATS1 1445/4885 |
| US-10294228-B2 | Breathing control modulating compounds, and methods of making and using same | MTNR1B, PDE3A, CHRM3 | SLC29A1 4518/4885TTK 4201/4885LATS1 3943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.